Ocular Therapeutix (NASDAQ: OCUL) reported Q3 EPS of ($0.47), $0.09 worse than the analyst estimate of ($0.38).

The third quarter 2015 results include $1.2 million in non-cash charges for stock-based compensation compared to $0.6 million in the third quarter of 2014.

As of September 30, 2015, cash and cash equivalents and marketable securities totaled $113.6 million. Cash used in operating activities was $9.7 million and $25.1 million for the three and nine month periods ended September 30, 2015, respectively. There was $15.0 million in outstanding debt as of September 30, 2015.

For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.